Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

In this online program experts discuss how to best use BTK inhibitors to enhance patient care across multiple B-cell malignancies. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Orlando and read expert commentaries on the new data to learn more about how and when to use BTK-targeted regimens for your patients with cancer.

Share

Program Content

Activities

Role of BTK Inhibitors
Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance to Refine Clinical Management Strategies
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: February 04, 2020

Expires: February 03, 2021

Activities

Next-Gen BTK Inhibitors
Next-Generation BTK Inhibitors and Why We Need Them
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2019

Expires: October 22, 2020

BTK Inhibitor FAQs
Frequently Asked Questions About BTK Inhibitor Use in B-Cell Malignancies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 21, 2020

Expires: February 19, 2021

Zanubrutinib in MCL
Meet Zanubrutinib, the Newest Bruton’s Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2020

Expires: March 23, 2021

Activities

BTKi Resistance
Overcoming BTK Inhibitor Resistance and Combination Strategies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi in MCL
Practical Case Discussions: BTK inhibitor Therapy for MCL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi in Frontline CLL
Practical Case Discussions: BTK inhibitor Therapy for Frontline CLL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi in Other Types
BTK Inhibitors in “Other” B-Cell Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

BTKi Safety
BTK Inhibitors for Managing Patients with B-Cell Malignancies: Safety and Optimal Use
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

Faculty

cover img faculity

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

cover img faculity

Jan A. Burger, MD, PhD

Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Alexey Danilov, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Knight Cancer Institute
Oregon Health and Science University
Portland, Oregon

cover img faculity

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly